Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
about
Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancerUpsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapyFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaA high-throughput drug screen for Entamoeba histolytica identifies a new lead and targetArsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathwayRedox-directed cancer therapeutics: molecular mechanisms and opportunitiesRole of endoplasmic reticulum stress in drug-induced toxicityMetal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer AgentsThe redox biology of schistosome parasites and applications for drug developmentDual effect of oxidative stress on leukemia cancer induction and treatmentReprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseasesA gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibitionArsenic toxicity to Saccharomyces cerevisiae is a consequence of inhibition of the TORC1 kinase combined with a chronic stress responseROS homeostasis and metabolism: a dangerous liason in cancer cellsTrxR1 as a potent regulator of the Nrf2-Keap1 response systemArsenic binding to proteinsDual Regulation of Cell Death and Cell Survival upon Induction of Cellular Stress by Isopimara-7,15-Dien-19-Oic Acid in Cervical Cancer, HeLa Cells In vitroDifferential transcriptional regulation of hypoxia-inducible factor-1α by arsenite under normoxia and hypoxia: involvement of Nrf2Paradoxical Roles of Antioxidant Enzymes: Basic Mechanisms and Health ImplicationsQuantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascadeFactors determining sensitivity and resistance of tumor cells to arsenic trioxideTRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress ResponseSelective targeting of selenocysteine in thioredoxin reductase by the half mustard 2-chloroethyl ethyl sulfide in lung epithelial cellsTargeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replicationCell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cellsROS-mediated platelet generation: a microenvironment-dependent manner for megakaryocyte proliferation, differentiation, and maturation.Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activitiesPenultimate selenocysteine residue replaced by cysteine in thioredoxin reductase from selenium-deficient rat liver.Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Acetaminophen reactive intermediates target hepatic thioredoxin reductaseNovel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia.Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assayCross-linking of thioredoxin reductase by the sulfur mustard analogue mechlorethamine (methylbis(2-chloroethyl)amine) in human lung epithelial cells and rat lung: selective inhibition of disulfide reduction but not redox cycling.Involvement of oxidative stress in the relapse of acute myeloid leukemia.Hepatocytes lacking thioredoxin reductase 1 have normal replicative potential during development and regeneration.Arsenic(III) species inhibit oxidative protein folding in vitro.Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growthA novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.Evaluation of the carcinogenicity of inorganic arsenic.Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase.
P2860
Q22000765-F2CEBC4C-24A0-4F31-8A3A-7D26E4EDB37DQ24597964-A7CF3679-3132-4563-9258-96B881B4E86EQ24605527-58C979AF-2974-4EC5-B1B5-CFA9E5E936B3Q24623736-70E13031-B9C0-491A-8681-FAB519597EA4Q24623800-79221FD5-AE2B-46FC-A4EF-435B26A76C46Q24645584-A07BDC4B-6309-4FA4-80F6-8E3755417F30Q26765518-D45FE048-A945-4B19-8ECD-E0B1CBB62D57Q26800031-C3BA51B8-057B-44E0-96E3-243F75329CE5Q26829701-DA42601E-2BAD-4A93-9EDA-2C9202B6A71FQ26866544-43F3F481-6FBE-4F43-98C7-FFA985AB99CAQ27003233-28C90214-E62D-42A5-8DD3-EF4C0815DFF5Q27671675-136FF90B-A6E2-48CC-BAC9-568A87B8523BQ27930076-ABE117AA-123C-4264-B55D-BB54DCEBD30FQ28075971-DC2E78BD-DEEB-4068-999D-73CA055D1F5BQ28080723-990CE997-8FF6-4C22-8452-D30C79E903CDQ28389752-3D855F2A-4AFC-4FDF-8C21-AB7052CD1649Q28390946-315893BD-D41E-4C46-9DBC-7F6E2DA8F75EQ28390987-44CFF947-0512-453F-B7CD-2C5717AB2F58Q28392715-E98011F9-AA4F-41C8-A5A2-42B5540794F1Q28472122-8127971C-D349-4488-8213-18E7A7181395Q28483625-A5CC243C-27C4-4C31-8264-A99A10373AA2Q28548386-89782B52-11A4-480B-8FEB-61CE7FF2D065Q28572034-FB38CDA0-1FD8-414A-98F9-018013513B37Q33304452-DF9FB82C-D638-4F8D-81D7-E704A77630B1Q33326607-641B35C1-EE17-4BA6-B4C2-389D95BAD9D3Q33409045-3616870A-0132-42BD-80AE-85C30CDDF85FQ33421722-1E34C5BB-B2D6-4188-A88A-7E777A5A87B4Q33427719-1B70D032-1BB2-443C-9A87-4D7E0C4C22A5Q33551142-5F816DF3-017D-4CC2-9DD0-3A1C44022665Q33662334-194DF884-B173-4A9A-9AD7-C35EC05A0052Q33732606-07CCD852-17F8-4270-A2E1-E87C6264F5E6Q33801828-0B25DB98-7A39-490B-988B-305747742A49Q33804630-67F88F69-042F-4ABC-AB4E-DB35316C7F8FQ33832446-6617FAE9-3072-4B5A-8D5A-3B3AEC2227E4Q33951227-2CD84610-AB27-4053-8628-F5E11B026F36Q33968624-C506FB75-79C5-478B-8270-6B7E63E7B5E3Q33976179-FBD66227-9F8D-42E1-A47A-C66245A47912Q34145056-F50D2CF8-CD46-4695-9504-1CA77E1621EBQ34371580-F501E72D-4011-4966-8A50-A0534A9CA9DCQ34558945-34EF56AF-8F58-4548-8C3E-E5D52E782D74
P2860
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
@ast
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
@en
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
@nl
type
label
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
@ast
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
@en
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
@nl
prefLabel
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
@ast
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
@en
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
@nl
P2860
P356
P1476
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
@en
P2093
Eng-Hui Chew
P2860
P304
12288-12293
P356
10.1073/PNAS.0701549104
P407
P577
2007-07-18T00:00:00Z